Talk:Infliximab

This link is not good
http://www.reuters.com/newsArticle.jhtml?type=healthNews&storyID=6059613

This link is not good, it is in the article where the FDA gives a warning. — Preceding unsigned comment added by 192.132.64.2 (talk) 00:59, 22 June 2005 (UTC)

Page merging
I see no reason to not merge the pages. --zandperl 02:22, 10 January 2006 (UTC)

I deleted it. It was a clone. JFW | T@lk  18:15, 12 January 2006 (UTC)

Indications
I note that the indications are American -- they differ in other countries Barry Zuckerkorn 19:36, 24 January 2006 (UTC)

Also used for chronic uveitis and sarcoidosis
I miss the mention of Infliximab for the treatment of chronic uveitis and sarcoidosis. On patients websites for these diseases in both Europe and the United States you will find plenty of people following a succesfull long term treatment with Infliximab. Currently all medical insurance plans in the U.S. cover Infliximab for the treatment of sarcoidosis. There has also been a double blind randomised placebo controlled study on 137 sarcoidosis patients being treated with Infliximab. The study suggests a limited improvement in short term lung sarcoidosis patients and a significant improvement in patients with chronic refractory sarcoidosis. Types of extra pulmonary sarcoidosis like neurosarcoidosis seem to show the best reaction to the treatment.

For this comment I refer to the AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 174 2006

for infliximab and uveitis http://ard.bmj.com/cgi/content/abstract/66/4/548

patient websites:

groups.msn.com/sarcoidbuddies http://groups.msn.com/BesnierBoeckSarcoidose —Preceding unsigned comment added by 217.136.229.100 (talk) 15:02, 30 May 2008 (UTC)

Should Crohn's be considered an autoimmune condition
Crohn's does not represent the product of anti-self immunity. — Preceding unsigned comment added by 83.70.249.174 (talk) 01:51, 25 October 2006 (UTC)

high risk of tuberculosis
I miss the explicit warning for the high risk of reactivation of latent tuberculosis infection (LTBI), which is 5-10% in persons with LTBI on infliximab. Since the classical granuloma formation is absent the reactivation tuberculosis manifests itself in a severe disseminated form. Before startin infliximab screening for LTBI is needed. Persons from countries with a high tuberculosis prevalence need special attention. Sytze Keizer Tuberculosis Chest Physician, Amsterdam —The preceding unsigned comment was added by 212.123.200.82 (talk) 08:37, 23 March 2007 (UTC).


 * Absoluut. De vraag is of een Mantouxtest voldoende is, of dat er gescreend moet worden met interferon of ELISPOT. JFW | T@lk  14:42, 1 April 2007 (UTC)
 * translation please - Rod57 (talk) 13:41, 9 February 2016 (UTC)

TB: This is a class effect: An increased susceptibility to tuberculosis or reactivation of latent tuberculosis should be considered a class characteristic of TNF blocking agents. The clinical picture of latent tuberculosis may be atypical in these patients (for example, miliary or extrapulmonary presentations) as has been seen with other immunocompromised patients (category C evidence 177–179 181–183). There have been more reported cases of tuberculosis as a proportion of the total number of individuals treated in patients using infliximab and adalimumab than etanercept (category C evidence177–179 181 183 185). This may be due in part to the fact that populations treated with the various TNF blocking agents differ and the data come from registries and voluntary reporting systems. No head-to-head comparisons among TNF blocking agents have been done and thus no definitive data on comparisons between these agents are available regarding the incidence of reactivation of latent tuberculosis. infections have been treated adequately (category D evidence 177 180 182–184 187–190; FDA). D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, P Emery, E C Keystone, M H Schiff, P L C M van Riel, M E Weinblatt, and M H Weisman Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 Ann Rheum Dis, Nov 2006; 65: iii2 - iii15
 * Neither this article or Tuberculosis seem to describe this adequately - where should it go ? - Rod57 (talk) 13:41, 9 February 2016 (UTC)

Should we have a section for controversies?
I was doing some research on the deceptive marketing practices of a different drug company and kept coming up with mentions of some pretty astounding deceptions used to market Remicade and/or get it to be a covered expense. I have no opinion on the drug one way or another but if you google the name and the wrod deceptive, you'll see what c omes up. These are well decumented events. I don't want to step in add a section of other frequent contributors feel it isn't warrented. I was merely surprised that no mention was made in the article of the C.A.R.E. Scam and the price-fixing scandal.LiPollis 10:52, 26 June 2007 (UTC)

IBS QOL
Improvement in many conditions is spectacular. In IBD, suggests the HRQOL is persistently improved. JFW | T@lk  14:42, 1 April 2007 (UTC) IBS or IBD? IBD makes sense, IBS does not — Preceding unsigned comment added by 198.49.6.225 (talk) 10:53, 6 April 2016 (UTC)

Cancer risk
Studies(published by the AMA) show that patients taking he rheumatoid arthritis drugs Remicade® (infliximab) or Humira® (adalimumab)have, on average, a three fold increased risk of developing cancer http://cancer.nchmd.org/news.aspx?id=36984 the study mentioned is:

Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serous infections and malignancies. Journal of the American Medical Association. 2006;295:2275-2285. —The preceding unsigned comment was added by 71.230.43.224 (talk) 04:17, 2 May 2007 (UTC).

Broken refs
I put the word out to the original contributor to repair the broken refs, if possible. See User:Statesman 88. MaxEnt (talk) 03:26, 5 December 2007 (UTC)

Golimumab not listed?
Simponi, aka golimumab, was recently approved. Ronabop (talk) 05:21, 26 April 2009 (UTC)

mix of trade names and generic names
hi. just a quick note to say having just read the article i found the mix of trade names and generic names (sometimes in the same sentence!) when discussing drugs quite confusing. i appreciate when discussing trial results it may be more appropriate to include the trade name of the particular brand used but when discussing modes of action, ie in the pharmocology section, should only generic names be used? anyway i dont kno if people agree and i wouldnt kno how to change the article myself anyway! —Preceding unsigned comment added by 77.98.220.164 (talk) 15:01, 7 December 2009 (UTC)

Treatment For / Sarcoidosis
Since I am waiting for approval to start a treatment using Infliximab, I thought I would suggest that Sarcoidosis be added to one of the conditions this medication is designated as a treatment for. The NeuroSarcoidosis Wiki page does list it. — Preceding unsigned comment added by 63.67.211.220 (talk) 15:10, 19 August 2011 (UTC)

Not an engineered protein
Not being a biotech, /me still thinks it ain't an engineered protein, and should be categorized with mAb's only. 46.138.66.66 (talk) 13:31, 5 November 2011 (UTC)

Chimeric or Humanized, not both.
As someone who has worked in the field of mAbs, it seems misleading to characterize this as both chimeric (see right box, and text), and humanized. If the mAb is humanized (which has a very specific meaning in this context) it is no longer considered chimeric. Since Infliximab has the "xi" it is, by definition, chimeric, not humanized. Remove "humanized" from the description. — Preceding unsigned comment added by Scott8586 (talk • contribs) 19:18, 16 April 2012 (UTC)
 * Update: changed it myself. — Preceding unsigned comment added by Scott8586 (talk • contribs) 19:25, 16 April 2012 (UTC)

External links modified
Hello fellow Wikipedians,

I have just added archive links to 1 one external link on Infliximab. Please take a moment to review my edit. If necessary, add after the link to keep me from modifying it. Alternatively, you can add to keep me off the page altogether. I made the following changes:
 * Added archive https://web.archive.org/20061009085444/http://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf to http://www.fda.gov/medwatch/safety/2006/May_PIs/Remicade_PI.pdf

When you have finished reviewing my changes, please set the checked parameter below to true to let others know.

Cheers. —cyberbot II  Talk to my owner :Online 07:38, 18 October 2015 (UTC)

Can we subdivide Pharmacology section
It's a mix of general discussion of TNF inhibitors and specifics about Infliximab. Could move most to a section Mode of action - which can have a brief section comparing with other TNF inhibitors ? - Rod57 (talk) 13:18, 9 February 2016 (UTC)

Remsima may become the second approved biosimilar in the U.S
FDA Staff Gives Infliximab Biosimilar Rave Review may warrant a mention of biosimilars ? - Rod57 (talk) 13:31, 9 February 2016 (UTC)

External links modified
Hello fellow Wikipedians,

I have just modified one external link on Infliximab. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:
 * Added archive https://web.archive.org/web/20110713111255/http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812 to http://www.jnj.com/connect/NewsArchive/all-news-archive/20071106_141812

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

Cheers.— InternetArchiveBot  (Report bug) 19:47, 13 November 2017 (UTC)

Reversal
What is the cure or reversal of this drug and symptoms in body??? 2601:346:4301:8F50:A031:FC35:7DC1:7075 (talk) 22:28, 31 December 2021 (UTC)